Prediction of no‐reflow and major adverse cardiovascular events with a new scoring system in STEMI patients

Bayramoğlu, Adil; Taşolar, Hakan; Kaya, Ahmet; Tanboğa, İbrahi̇m Hali̇l; Yaman, Mehmet; Bektaş, Osman; Günaydın, Zeki Yüksel; Oduncu, Vecih

doi:10.1111/joic.12463

Cited by 30 publications

(34 citation statements)

References 24 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This study revealed a dual prognostic utility of CHA2DS2-VASc for both suboptimal reperfusion and short-term mortality. This coincides with many studies who found a useful surrogate measure of in-hospital mortality independent of nore low [5,12,[14][15][16][17][18].…”

Section: Discussionsupporting

confidence: 89%

See 1 more Smart Citation

Evaluation of the predictive value of CHA2DS2-VASc Score for no-reflow phenomenon in patients with ST-segment elevation myocardial infarction who underwent Primary Percutaneous Coronary Intervention

El-Moneum¹

2019

J Cardiol Cardiovasc

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 89%

“…Bayramoğlu, et al [14] declared the impacts of long stent (> 20 mm) and thrombus grade on no-re low risk. Odds ratios 3.607 (1.932-6.734), and 3.139 (1.081-9.113), respectively.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the predictive value of CHA2DS2-VASc Score for no-reflow phenomenon in patients with ST-segment elevation myocardial infarction who underwent Primary Percutaneous Coronary Intervention

El-Moneum¹

2019

J Cardiol Cardiovasc

View full text Add to dashboard Cite

show abstract

“…In conclusion, traditional CHA2DS2-VASc model is a useful easily available risk assessment tool to stratify STEMI patients who are more prone to no-reflow and failed reperfusion. Besides, we have a useful surrogate measure of in-hospital mortality independent of no-reflow [19,25,32,33,34,35,36,37,38].…”

Section: Discussionmentioning

confidence: 99%

CHA2DS2-VASc Score as an Independent Predictor of Suboptimal Reperfusion and Short-Term Mortality after Primary PCI in Patients with Acute ST Segment Elevation Myocardial Infarction

et al. 2019

View full text Add to dashboard Cite

Background and objectives: We aimed to demonstrate the clinical utility of CHA2DS2-VASc score in risk assessment of patients with STEMI regarding adverse clinical outcomes particularly no-reflow phenomenon. Materials and Methods: We designed a retrospective cohort study using the data of Tehran Heart Center registry for acute coronary syndrome. The study included 1331 consecutive patients with STEMI who underwent primary angioplasty. Patients were divided into two groups according to low and high CHA2DS2-VASc score. Angiographic results of reperfusion were inspected to evaluate the association of high CHA2DS2-VASc score and the likelihood of suboptimal TIMI flow. The secondary endpoint of the study was short-term in-hospital mortality of all cause. Results: The present study confirmed that CHA2DS2-VASc model enables us to determine the risk of no-reflow and all-cause in-hospital mortality independently. Odds ratios were 1.59 (1.30–2.25) and 1.60 (1.17–2.19), respectively. Moreover, BMI, high thrombus grade, and cardiogenic shock were predictors of failed reperfusion (odds were 1.07 (1.01–1.35), 1.59 (1.28–1.76), and 8.65 (3.76–24.46), respectively). We showed that using a cut off value of ≥ two in CHA2DS2-VASc model provides a sensitivity of 69.7% and specificity of 64.4% for discrimination of increased mortality hazards. Area under the curve: 0.72 with 95% CI (0.62–0.81). Conclusions: Calculation of CHA2DS2-VASc score applied as a simple risk stratification tool before primary PCI affords great predictive power. Furthermore, incremental values are obtained by using both CHA2DS2-VASc and no-reflow regarding mortality risk assessment.

show abstract

“…Previous studies have identified various predictors of NRP. For example, Bayramoglu et al [32] and Mazhar et al [33] found that advanced age, lower-left ventricular ejection fraction, stent length of ≥20 mm, thrombus burden, Killip class ≥3, and longer pain-to-balloon time are independent predictors of NRP. Similarly, anterior infarctions, [34] hypertension, dyslipidemia, a history of smoking, and a history of tobacco use [35] have also been shown to be associated with NRP.…”

Section: Discussionmentioning

confidence: 99%

New CHA2DS2-VASc-HSF score predicts the no-reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction

Zhang

Sun

2020

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Background: The no-reflow phenomenon (NRP) is a serious complication of primary percutaneous coronary intervention (PPCI) and is an independent predictor of poor prognosis. We aimed to find a simple but effective risk stratification method for the prediction of NRP. Methods: This retrospective single-center study included 454 consecutive patients diagnosed with acute STsegment elevation myocardial infarction (STEMI) and treated by PPCI, who were admitted to our emergency department between January 2017 and March 2019. The patients were divided according to the post-PPCI thrombolysis in the myocardial infarction flow rate: the NRP group and the control group. The CHADS 2 , CHA 2 DS 2-VASc, and CHA 2 DS 2-VASc-HSF scores were calculated for all the patients in this study, and multivariable regression and receiver operating characteristic curve analyses were conducted to determine the independent predictors of NRP and the predictive value of the three scores. Results: A total of 454 patients were analyzed in this study: 80 in the no-reflow group and 374 in the control group. The incidence of NRP was 17.6%. Creatine kinase-myocardial band, Killip class, stent length, and multivessel disease also independently predicted NRP. The CHA 2 DS 2-VASc-HSF score had a higher predictive value than the other two scores, and a CHA 2 DS 2-VASc-HSF score of ≥4 predicted NRP with a sensitivity of 72.5% and specificity of 66.5% (area under the curve: 0.755, 95% confidence interval [0.702-0.808]). Conclusion: Although the CHADS 2 , CHA 2 DS 2-VASc, and CHA 2 DS 2-VASc-HSF scores can all be used as simple tools to predict NRP, our findings show that the CHA 2 DS 2-VASc-HSF score had the highest predictive value. Thus, the CHA 2 DS 2-VASc-HSF score may be an optimal tool for predicting high-risk patients.

show abstract

Prediction of no‐reflow and major adverse cardiovascular events with a new scoring system in STEMI patients

Abstract: This new score, which can be calculated in STEMI patients before PCI and used to predict no-reflow in STEMI patients, may help physicians to estimate the development of no-reflow in the pre-PCI period.

Cited by 30 publications

References 24 publications

Evaluation of the predictive value of CHA2DS2-VASc Score for no-reflow phenomenon in patients with ST-segment elevation myocardial infarction who underwent Primary Percutaneous Coronary Intervention

Evaluation of the predictive value of CHA2DS2-VASc Score for no-reflow phenomenon in patients with ST-segment elevation myocardial infarction who underwent Primary Percutaneous Coronary Intervention

CHA2DS2-VASc Score as an Independent Predictor of Suboptimal Reperfusion and Short-Term Mortality after Primary PCI in Patients with Acute ST Segment Elevation Myocardial Infarction

New CHA2DS2-VASc-HSF score predicts the no-reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction

Contact Info

Product

Resources

About